Santhera Pharmaceuticals Holding AG
Hammerstrasse 49
CH-4410 Liestal / Switzerland
Phone +41 61 906 89 50
Fax +41 61 906 89 51
www.santhera.com

Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting

Liestal, Switzerland, May 20, 2014 – Santhera Pharmaceuticals (SIX: SANN) announced today that at its Annual Shareholders' Meeting, a large majority of shareholders represented approved all proposals by the Board of Directors (Board). In particular, shareholders voted in favor of the proposed appropriation of the results and the creation of new authorized and conditional capitals. Board members Martin Gertsch (Chairman) and Jürg Ambühl were both re-elected.

A total of 2,057,189 shares or 44.9 % of the share capital was represented at the Shareholders' Meeting. Details of the agenda items are available from the Company's website www.santhera.com under *Investors/Shareholders' Meeting.*

Shareholders approved the 2013 Annual Report, the annual financial statements and the consolidated financial statements as well as the proposed appropriation of the results. The reports of the auditors were acknowledged and the members of the Board and the management discharged. Shareholders also approved a renewal of authorized and both an increase of existing conditional share capital and a creation of additional conditional share capital. In addition, several amendments to the Company's Articles of Incorporation as required by the Ordinance Against Excessive Compensation ("Minder Initiative") were voted on favorably.

Martin Gertsch was re-elected as member and elected as Chairman of the Board. Shareholders also re-elected Jürg Ambühl as Board member. Both gentlemen were elected as members of the Compensation Committee. Finally Ernst & Young, Basel, were re-appointed as auditors and Balthasar Settelen, Basel, as independent proxy. All elections are for a period of one year until the next ordinary shareholders' meeting.

Martin Gertsch, Chairman of the Board, explained: "In line with the mandate received last year, we preserved our key assets and advanced their development. The recently communicated positive outcome of the Phase III study in Duchenne Muscular Dystrophy is an important milestone for Santhera's future. We now anticipate increasing interest from existing and new investors, licensees as well as the possibility of income from licensing in the short to mid-term. We further filed the marketing authorization application for Raxone® in the treatment of Leber's Hereditary Optic Neuropa-

thy and expect a decision by the European Medicines Agency in the first half of 2015." Referring to the Santhera's financial situation, he commented: "Looking ahead, we expect to finance the Company's operations by income from Raxone® sales, licensing opportunities and appropriate use of authorized and conditional capital."

* * *

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases.

Santhera recently announced the re-filing of a Marketing Authorization Application (MAA) for Raxone® in Leber's Hereditary Optic Neuropathy (LHON) based on additional clinical efficacy data and following pre-filing advice from EU member states. The compound has been granted orphan drug designation in the EU and the US. Raxone® would become the first product authorized for the treatment of this rare, inherited disease which otherwise invariably leads to blindness. Santhera expects a decision from the European Medicines Agency in the first half of 2015. Earlier this year, the French National Agency for the Safety of Medicine and Health Products granted a temporary authorization for use for Raxone® in LHON patients in France based on a data package comparable to the submitted MAA dossier.

On May 13, 2014, Santhera announced a positive outcome for its Phase III DELOS trial in Duchenne Muscular Dystrophy (DMD). The DELOS study randomized 65 DMD patients who were 10-18 years of age and who were not using concomitant corticosteroids. The study met the primary endpoint, a statistically significant difference between Catena®/Raxone® and placebo in the change from baseline to week 52 in Peak Expiratory Flow. Peak Expiratory Flow is a measure of respiratory muscle strength, the decline of which is a major contributing factor to morbidity and mortality in DMD. Catena®/Raxone® (900 mg/day) was safe and well tolerated with adverse event rates comparable to placebo.

Santhera is collaborating with the National Institutes of Health on a placebo-controlled Phase II clinical trial for the treatment of primary progressive Multiple Sclerosis (ppMS), a currently untreatable disease affecting approximately 60,000 patients in North America and 85,000 in Europe.

Santhera holds full global patent and/or commercialization rights to all of its clinical development programs for Catena®/Raxone®. For further information, please visit the Company's website www.santhera.com.

Raxone® and Catena® are trademarks of Santhera Pharmaceuticals.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.